CLZX-205 | m-entrepreneurship.com

Product Name :
CLZX-205

Search keywords :
CLZX-205

drugId :
null

Target Vo:
Cyclin-dependent kinase 9

Target Vo Short Name :
CDK9

Moa_Name:
Cyclin-dependent kinase 9 inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Shenyang Pharmaceutical University

Active Company_Name :
Shenyang Pharmaceutical University

Active Indication_Name:
Colorectal Neoplasms

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Preclinical

China Highest Status:
Preclinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
FOXP3 Antibody
PI3 Kinase p110 gamma Antibody (YA690)
Beta-Catenin Antibody: Beta-Catenin Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 85 kDa, targeting to Beta-Catenin. It can be used for WB,IHC-P,IF,IP assays with tag free, in the background of Human, Mouse.

Author: Betaine hydrochloride

Related Posts